Illinois clinic one of first places in the country to offer new device to spinal cord injury patients
With electrodes stuck to different parts of his back along his spine, Shane Callahan practiced walking on a recent day — with help from an exercise specialist and a harness that helped hold him upright.
Callahan has a spinal cord injury, so he wasn't supporting all of his own weight or moving his legs by himself. But something had changed. He had a little bit of sensation in his feet.
'It's pretty strange,' said Callahan, 22, of Lockport, who was injured as a passenger in a car accident 1 1/2 years ago. Since he started using the device with the electrodes, he said, he can feel his feet touching surfaces, though they still can't feel pain or temperature. 'I think there's definitely noticeable progress.'
The device, called the ARC-EX, delivers electrical pulses to his spine during his sessions at Next Steps Chicago, a neurological rehabilitation clinic in Willow Springs. The device was approved by the U.S. Food and Drug Administration in December, with some experts hailing it as a milestone in therapy for people with spinal cord injuries. Next Steps is one of the first two clinics in the country offering it.
'It's pretty miraculous,' said Mary Jones, a physical therapist and director of operations at Next Steps Chicago. 'I spent my career working toward this and to see it come to fruition is nothing short of amazing.'
Now, during Callahan's appointments at Next Steps, neuro-adaptive exercise specialist Creighton Goss attaches electrodes to the back of Callahan's neck along his cervical spine and then midway down his back, near his thoracic spine. Thin electrical cables connect the electrodes to the ARC-EX device, which delivers continuous electrical pulses throughout Callahan's appointment.
The stimulation doesn't hurt, but 'It definitely wakes you up,' Callahan said with a smile.
The ARC-EX is not the first device to deliver electrical stimulation through the skin to help people with spinal cord injuries. But unlike other commercially available devices, the ARC-EX delivers stimulation directly to the spine, rather than to other parts of the body that a person wishes to move, such as to an arm or a leg. The idea is to restore hand strength and sensation even when stimulation is no longer used.
The device is supposed to be used for up to an hour a day, alongside therapy or training, to help improve hand strength and sensation for people with incomplete spinal cord injuries. About two-thirds of people with spinal cord injuries in the U.S. have incomplete injuries, meaning that though their movement may be extremely limited, their spinal cords have not completely lost the ability to transmit messages to and from the brain.
'Some instruction from the brain gets through but not enough to create a movement, so we're providing an amplification of that signal from the brain,' said Dave Marver, CEO of Onward Medical, the company that sells the device.
Dr. Arun Jayaraman, executive director of the Technology & Innovation Hub at Chicago rehabilitation hospital Shirley Ryan AbilityLab, who is not involved with Next Steps, called the device 'an additional tool' that can be used to improve spinal cord signals to the limbs. He said it's the first device of its kind to be FDA-approved and available for everyday use by clinicians, rather than just for research purposes. The AbilityLab has an agreement to use the device for its research studies in stroke and other medical conditions later this year.
The device's FDA approval is 'huge' for the spinal cord injury community, said Marco Baptista, chief scientific officer with the Christopher and Dana Reeve Foundation, which helped support the device's development with an investment in Onward. Philanthropic venture fund SCI Ventures, which was co-founded by the foundation and other nonprofits, now holds that investment, and any revenue received from the investment will go toward supporting more research, Baptista said.
'One, this can be a device that can help people, and, two, it provides this path forward that other therapies can then follow,' Baptista said.
Next Steps Chicago, a standalone nonprofit, helped test an earlier version of the device and has always felt it's important to bring cutting-edge technologies into the community, Jones said.
'This is a catastrophic lifelong condition,' Jones said of spinal cord injuries. 'To make somebody's life a little bit easier, to give them 10% improvement, that's a big deal for someone who hasn't moved their arm or is dependent on someone else for round-the-clock care.'
The device costs clinics about $40,000, Marver said — not a small price tag, but also not the most expensive piece of equipment a clinic like Next Steps uses.
In a study funded by Onward and published in May in the peer-reviewed journal Nature Medicine, 72% of participants saw improved strength and function in their hands and arms after using the device. The FDA specifically approved the device to be used to improve hand sensation and strength.
Improving hand function is a priority for many people with spinal cord injuries, Marver said, sometimes even more so than regaining the ability to walk.
'They need their hands to get through activities of daily living, to feed themselves, to clothe themselves, to go to the bathroom,' Marver said. 'These are all things that introduce independence, dignity, quality of life.'
The device doesn't work for everyone, but so far Next Steps has seen about a dozen patients have positive results, including Callahan, Jones said. Though Callahan still has hand function, the device has helped with other areas of his body, Jones said.
Callahan said he'd been a patient at Next Steps for about a year when Jones asked him if he wanted to try the ARC-EX device.
'She was explaining the research behind it and the possible benefits of using it, and it seemed it was applicable to my injury, so I thought why not,' Callahan said.
Callahan uses a wheelchair and is paralyzed from the diaphragm down. After his accident, he spent about two months as an inpatient at AbilityLab and then another six months doing outpatient rehab with the AbilityLab.
Now, he goes to Next Steps about three times a week, for two hours at a time, where he practices movement in the treatment gym. At a recent appointment, Goss had him kneel in front of a low table, which he used to brace himself, using his arms. Goss then slowly helped Callahan move his legs back and forth, an exercise designed to help him practice shifting weight from one leg to the other.
Callahan isn't sure how much strength, movement or sensation he'll ever regain. Everyone and every injury is different. 'Nothing is guaranteed,' Callahan said, but he's trying to recover as much as he can.
'It would definitely improve my quality of life, not just for me, but for my family,' Callahan said of the prospect of regaining more function.
'We're hoping you walk in one day and say, 'Peace out, I'm done,'' Goss said. 'That would be the goal.'
'That would be the goal,' Callahan agreed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Recall issued for potential significant risk with use of Zicam, Orajel swabs. What to know
A "potential microbial contamination" has lead to the recall of several cold nasal swabs and baby teething swabs, according to an announcement from the U.S. Food and Drug Administration June 9. All lots of Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs, and Orajel Baby Teething Swabs have been recalled due to the potential contamination. The swabs can "potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections." Here's what you should know. Church & Dwight Co. is recalling all lots of Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs, and Orajel Baby Teething Swabs due to potential microbial contamination identified as fungi in cotton swab components, according to a June 9 news release. The recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by the recall, the news released from the FDA said. As of June 9, "no serious adverse events" associated with the affected product have been reported, the FDA said. Recalled Zicam and Orajel swabs included in the recall are: Zicam Cold Remedy Nasal Swabs, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam Nasal AllClear Swabs, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel Baby Teething Swabs, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. "Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. "The risk is highest — potentially severe or life-threatening — among children and individuals with compromised immune systems or other underlying medical conditions." The recalled products were distributed nationwide in the United States and in Puerto Rico. Consumers who have purchased any of the recalled products should stop using the product immediately, the FDA said. Go to or call the Consumer Relations team at 800-981-4710 for a full refund. This article originally appeared on Treasure Coast Newspapers: Zicam recall: cold nasal swabs. Also Orajel baby teething swabs
Yahoo
3 hours ago
- Yahoo
Over A Million Eggs Were Just Recalled — Here Are The States Impacted
The August Egg Company — which sells eggs under multiple brand names — announced a major recall on June 6, 2025. According to a company statement shared by the U.S. Food and Drug Administration, the recall was sparked by an outbreak of salmonella. Over 1.7 million eggs were affected, and, at the time of writing, at least 79 people have been sickened by the outbreak. Of those, 21 have been hospitalized. No deaths have been reported. The recall affects eggs sold in Arizona, California, Illinois, Indiana, Nebraska, Nevada, New Mexico, Washington state, and Wyoming. The eggs were sold at multiple retailers, including Walmart and Safeway. If you purchased brown cage-free or certified organic eggs in those states between February 3 and May 15, you should check the packaging for the plant code numbers P-6562 or CA5330. For a full list of impacted brands with carton UPC numbers, check the FDA website. "August Egg Company's internal food safety team is also conducting its own stringent review to identify what measures can be established to prevent this situation from recurring," the company said in the statement, and it won't be selling any fresh eggs for at least a month. The U.S. Centers for Disease Control and Prevention (CDC) is also investigating the outbreak. Eggs may be getting more expensive at the grocery store — but you should still dispose of any eggs affected by the recall. Or get a full refund by returning the eggs to your retailer. For questions, you can contact the August Egg Company between 9 a.m. and 5 p.m. Pacific Time at 1-800-710-2554. Read more: 14 Foods You Should Never Freeze The U.S. Department of Agriculture recommends thoroughly cleaning any surfaces that came in contact with the recalled eggs. Hot, soapy water is great, and it's best to use single-use paper towels to prevent spreading the bacteria. Follow that up by sanitizing any surfaces with a diluted bleach solution or commercial spray. Dishes can be both cleaned and sanitized right in the dishwasher. Keep an eye out for symptoms of salmonella, too. Most people have mild symptoms, but people with compromised immune systems, children under the age of 5, and adults over 65 are at a higher risk of serious infection, notes Symptoms — which include diarrhea and vomiting — typically start between six hours and six days after infection. You may experience fever and stomach cramps, too. Try to stay hydrated and get plenty of rest. Most infections don't require treatment, but it's a good idea to seek medical attention if you're immunocompromised or start to experience severe symptoms. This isn't the first time that an egg recall has affected millions. Still, you can steer clear of these egg cooking mistakes to stay safe. Check eggs for cracks before you purchase them, store your eggs properly, and keep an eye out for other recalls. For more food and drink goodness, join The Takeout's newsletter. Get taste tests, food & drink news, deals from your favorite chains, recipes, cooking tips, and more! Read the original article on The Takeout.
Yahoo
7 hours ago
- Yahoo
Journey Medical Corporation Announces Emrosi™ Featured on 'The Balancing Act' Airing on Lifetime TV
National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz., June 09, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) ('Journey Medical' or 'the Company', 'we', or 'our'), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ('FDA') approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that a new segment of 'The Balancing Act®' airing on Lifetime TV and sponsored by the Company featured Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), its FDA-approved treatment for inflammatory lesions of rosacea in adults. The segment premiered nationwide on Monday, June 9, at 7:30 a.m. PT / ET and provided expert insights on lifestyle considerations and treatment options for managing rosacea. 'We're proud to see Emrosi featured on 'The Balancing Act,' bringing national visibility to what we believe is a potential paradigm shift in the treatment of rosacea,' said Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Journey Medical. 'This segment is an important opportunity to educate patients, caregivers and healthcare providers about Emrosi's unique formulation and benefits, as well as our broader commitment to advancing dermatologic care through innovative, patient-focused solutions.' The feature included insights from Pura Dermatology's Saurabh Lodha, MD, FAAD, who discussed Emrosi's unique formulation and its significance in the treatment landscape for rosacea. Approved by the U.S. Food and Drug Administration (FDA) in November 2024, Emrosi is the lowest-dose oral minocycline available, offering patients an effective treatment option with a favorable safety profile. It is available by prescription at specialty pharmacy chains. In addition to the June 9 premiere, the segment will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET. It can also be viewed on the show's website, About RosaceaRosacea is a chronic, relapsing, inflammatory skin condition that most commonly presents with symptoms such as deep facial redness, acne-like inflammatory lesions (papules and pustules) and spider veins (telangiectasia). According to The National Rosacea Society, it is estimated that rosacea affects over 16 million Americans and as many as 415 million people worldwide. Rosacea is most frequently seen in adults between 30 and 50 years of age. Surveys conducted by The National Rosacea Society report that more than 90 percent of rosacea patients said their condition had lowered their self-confidence and self-esteem, and 41 percent stated that it had caused them to avoid public contact or cancel social engagements. Among rosacea patients with severe symptoms, 88 percent said the disorder had adversely affected their professional interactions, and 51 percent said they had missed work because of their condition. Important Safety InformationIndication: EMROSI™ is indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. Adverse Events: The most common adverse reaction reported by ≥1% of subjects treated with EMROSI and more frequently than in subjects receiving placebo was dyspepsia. Contraindications: EMROSI should not be taken by patients who have a history of hypersensitivity to any of the tetracyclines. Warnings/Precautions: Cases of anaphylaxis, serious skin reactions (e.g., Stevens-Johnson syndrome), erythema multiforme, and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported postmarketing with minocycline use in patients with acne. If DRESS syndrome is recognized, discontinue EMROSI immediately. Use during the second and third trimesters of pregnancy, infancy and childhood up to the age of 8 years may cause permanent discoloration of the teeth and reversible inhibition of bone growth. Discontinue EMROSI use if Antibiotic-Associated Colitis occurs. Discontinue EMROSI if liver injury is suspected. Patients experiencing light-headedness, dizziness or vertigo should be cautioned about driving vehicles or operating heavy machinery. Clinical manifestations include headache, blurred vision, diplopia, and vision loss. Discontinue EMROSI immediately if symptoms occur. Symptoms may be manifested by fever, rash, arthralgia, and malaise. Discontinue EMROSI immediately if symptoms occur. Patients should minimize or avoid exposure to natural or artificial sunlight while using EMROSI. Tetracycline-class antibiotics are known to cause hyperpigmentation. EMROSI may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity, sclerae and heart valves. Because of the potential for drug-resistant bacteria to develop during the use of EMROSI, use EMROSI only as indicated. If superinfection occurs, discontinue EMROSI and institute appropriate therapy. Perform periodic laboratory evaluations of organ systems, including hematopoietic, renal and hepatic studies. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088 For full prescribing information, please visit About The Balancing ActThe Balancing Act® is a morning show created and produced by BrandStar that offers sensible solutions and essential information in a fun, entertaining format; providing resources to help people do life better. The Balancing Act features everything from delicious recipes, style makeovers and dream getaways to parenting tips and the latest news in health and wealth. Tune in to The Balancing Act weekdays at 7:30 a.m. (ET/PT) on Lifetime® and find all previously aired episodes on About Journey Medical CorporationJourney Medical Corporation (Nasdaq: DERM) ('Journey Medical') is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight FDA approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology's most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical's common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission ('SEC'). For additional information about Journey Medical, visit Forward-Looking StatementsThis press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words 'the Company', 'we', 'us' and 'our' may refer to Journey Medical. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words 'anticipate,' 'believe,' 'estimate,' 'may,' 'expect,' 'will,' 'could,' 'project,' 'intend,' 'potential' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales derive from products that may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results; competition could limit our products' commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful commercialization of our recently approved product, EmrosiTM, and any future product candidates that we may develop, in-license or acquire; clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties' cybersecurity; the substantial doubt about our ability to continue as a going concern; the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other risks described in Part I, Item 1A, 'Risk Factors,' in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Company Contact:Jaclyn Jaffe (781) 652-4500ir@ Media Relations Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@ in to access your portfolio